Philippe Gorphe1, Margarida Matias2, Caroline Even3, Charles Ferte2, François Bidault4, Gabriel Garcia4, Stéphane Temam3, France Nguyen5, Pierre Blanchard5, Yungan Tao5, François Janot3. 1. Department of Head and Neck Oncology, Gustave Roussy Institute, Villejuif, France Philippe.gorphe@gustaveroussy.fr. 2. Department of Medical Oncology, Gustave Roussy Institute, Villejuif, France. 3. Department of Head and Neck Oncology, Gustave Roussy Institute, Villejuif, France. 4. Department of Radiology, Gustave Roussy Institute, Villejuif, France. 5. Department of Radiotherapy, Gustave Roussy Institute, Villejuif, France.
Abstract
BACKGROUND: We reviewed the outcomes of patients with T3 laryngeal neoplasms with a fixed hemilarynx, a large gross tumor volume or a subglottic extension (SGE), treated with a laryngeal-preservation protocol with induction chemotherapy. PATIENTS AND METHODS: The study end-points were laryngo-esophageal dysfunction-free survival (LEDFS), laryngectomy-free survival (LFS), overall survival (OS), and disease-free survival (DFS). RESULTS: A total of 104 patients were included. The 2-year and 5-year OS rates were 70.4% and 54.5%, respectively. OS and DFS were independent of the treatment modality in the whole cohort (p=0.6546 and p=0.3006, respectively) and in patients with SGE (p=0.529 and p=0.255, respectively). The 2-year and 5-year LEDFS rates were 44.3% and 28.2%, respectively. LEDFS was not associated with initial hemilaryngeal fixation or SGE (p=0.5772 and p=0.0623, respectively). CONCLUSION: Chemoselection is feasible without compromised oncological or functional outcomes in patients with an initially fixed hemilarynx or subglottic extension. Copyright
BACKGROUND: We reviewed the outcomes of patients with T3 laryngeal neoplasms with a fixed hemilarynx, a large gross tumor volume or a subglottic extension (SGE), treated with a laryngeal-preservation protocol with induction chemotherapy. PATIENTS AND METHODS: The study end-points were laryngo-esophageal dysfunction-free survival (LEDFS), laryngectomy-free survival (LFS), overall survival (OS), and disease-free survival (DFS). RESULTS: A total of 104 patients were included. The 2-year and 5-year OS rates were 70.4% and 54.5%, respectively. OS and DFS were independent of the treatment modality in the whole cohort (p=0.6546 and p=0.3006, respectively) and in patients with SGE (p=0.529 and p=0.255, respectively). The 2-year and 5-year LEDFS rates were 44.3% and 28.2%, respectively. LEDFS was not associated with initial hemilaryngeal fixation or SGE (p=0.5772 and p=0.0623, respectively). CONCLUSION: Chemoselection is feasible without compromised oncological or functional outcomes in patients with an initially fixed hemilarynx or subglottic extension. Copyright